国际米兰-www.gjmlzww.com|官方中文网

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

11-072019

China NMPA Approves Bio-Thera Solutions' QLETLI®, A Biosimilar To Humira® (Adalimumab)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced t...
03-282019

Bio-Thera Solutions Announces Two Poster Presentations at the 2019 AACR Annual Meeting

Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies a...
01-232019

Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra® (Tocilizumab)

Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina Phase III clinic...

上一页 ···27 28 29 30 31 ··· 下一页